Byetta is an in injectable drug (exenatide) for the treatment of type 2 diabetes which is marketed by Amylin Pharmaceuticals and Eli Lilly. The drug was approved for use by the U.S. Food and Drug Administration for use in April 2005. 
Other SourceWatch Resources
- U.S. Food and Drug Administration, "Patient Information Sheet: Exenatide (marketed as Byetta)", May 27, 2005.
- Marc Longpre, "Diabetes campaign urges active lifestyle", PR Week, March 20, 2007.
|This article is a stub. You can help by expanding it.|